{"name":"BioMarin Pharmaceutical Inc.","slug":"biomarin","ticker":"BMRN","exchange":"NASDAQ","domain":"biomarin.com","description":"BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).","hq":"San Rafael, CA","founded":0,"employees":"3221","ceo":"Alexander Hardy","sector":"Biotech","stockPrice":57.28,"stockChange":1.06,"stockChangePercent":1.89,"marketCap":"$11.0B","metrics":{"revenue":1500000000,"revenueGrowth":17,"grossMargin":52.8,"rdSpend":921930000,"netIncome":348901000,"cash":1560609024,"dividendYield":0,"peRatio":31.8,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Rhgalns","genericName":"ELOSULFASE ALFA","slug":"elosulfase-alfa","revenue":500000000,"yoyGrowth":0,"percentOfTotal":33.3},{"name":"Aryplase","genericName":"GALSULFASE","slug":"galsulfase","revenue":400000000,"yoyGrowth":0,"percentOfTotal":26.7},{"name":"Aldurazyme","genericName":"LARONIDASE","slug":"laronidase","revenue":300000000,"yoyGrowth":0,"percentOfTotal":20},{"name":"Kuvan","genericName":"SAPROPTERIN","slug":"sapropterin","revenue":300000000,"yoyGrowth":0,"percentOfTotal":20}],"timeline":[{"date":"2003-01-01","label":"Aldurazyme first approved","drug":"Aldurazyme","drugSlug":"laronidase","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Aryplase first approved","drug":"Aryplase","drugSlug":"galsulfase","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Kuvan first approved","drug":"Kuvan","drugSlug":"sapropterin","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Rhgalns first approved","drug":"Rhgalns","drugSlug":"elosulfase-alfa","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Rhttp1 first approved","drug":"Rhttp1","drugSlug":"cerliponase-alfa","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Aldurazyme patent cliff ($1.2B at risk)","drug":"Aldurazyme","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Vimizim patent cliff ($400M at risk)","drug":"Vimizim","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":1200000000,"percentOfTotal":80,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Rhgalns","genericName":"ELOSULFASE ALFA","slug":"elosulfase-alfa","indication":"Mucopolysaccharidosis, MPS-IV-A","status":"marketed","revenue":500000000},{"name":"Aryplase","genericName":"GALSULFASE","slug":"galsulfase","indication":"Maroteaux-Lamy syndrome","status":"marketed","revenue":400000000},{"name":"Aldurazyme","genericName":"LARONIDASE","slug":"laronidase","indication":"Mucopolysaccharidosis, MPS-I","status":"marketed","revenue":300000000},{"name":"BMN 110 - Every Other Week","genericName":"BMN 110 - Every Other Week","slug":"bmn-110-every-other-week","indication":"Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)","status":"phase_3"},{"name":"BMN 110 - Weekly","genericName":"BMN 110 - Weekly","slug":"bmn-110-weekly","indication":"Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":300000000,"percentOfTotal":20,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Kuvan","genericName":"SAPROPTERIN","slug":"sapropterin","indication":"Reduce blood phenylalanine levels in PKU","status":"marketed","revenue":300000000},{"name":"RDD to Palynziq","genericName":"RDD to Palynziq","slug":"rdd-to-palynziq","indication":"Phenylketonuria (PKU) in patients with blood phenylalanine levels ≥600 μmol/L","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"cardiovascular","drugs":[{"name":"Vosoritide Injection","genericName":"Vosoritide Injection","slug":"vosoritide-injection","indication":"Other","status":"phase_2"},{"name":"BMN 111","genericName":"BMN 111","slug":"bmn-111","indication":"Achondroplasia (to increase adult height)","status":"phase_3"},{"name":"BMN 165","genericName":"BMN 165","slug":"bmn-165","indication":"Mucopolysaccharidosis IVA (Morquio A syndrome)","status":"phase_3"},{"name":"BMN 333","genericName":"BMN 333","slug":"bmn-333","indication":"Mucopolysaccharidosis type IIIB (MPS IIIB)","status":"phase_2"},{"name":"Placebo/rhASB","genericName":"Placebo/rhASB","slug":"placebo-rhasb","indication":"Maroteaux-Lamy syndrome (mucopolysaccharidosis VI)","status":"phase_3"},{"name":"BMN 110","genericName":"BMN 110","slug":"bmn-110","indication":"Tay-Sachs disease (late-infantile or juvenile onset)","status":"phase_3"},{"name":"N-acetylgalactosamine 4-sulfatase","genericName":"N-acetylgalactosamine 4-sulfatase","slug":"n-acetylgalactosamine-4-sulfatase","indication":"Morquio A syndrome (mucopolysaccharidosis IVA)","status":"phase_3"},{"name":"Phenoptin","genericName":"Phenoptin","slug":"phenoptin","indication":"Other","status":"phase_2"},{"name":"Roctavian","genericName":"VALOCTOCOGENE ROXAPARVOVEC","slug":"valoctocogene-roxaparvovec","indication":"Severe hereditary factor VIII deficiency disease","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Rhttp1","genericName":"CERLIPONASE ALFA","slug":"cerliponase-alfa","indication":"Late-infantile neuronal ceroid lipofuscinosis","status":"marketed"}]}],"pipeline":[{"name":"Rhgalns","genericName":"ELOSULFASE ALFA","slug":"elosulfase-alfa","phase":"marketed","mechanism":"VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes.","indications":["Mucopolysaccharidosis, MPS-IV-A"],"catalyst":""},{"name":"Aryplase","genericName":"GALSULFASE","slug":"galsulfase","phase":"marketed","mechanism":"Aryplase breaks down accumulated glycosaminoglycans in lysosomes to treat Maroteaux-Lamy syndrome.","indications":["Maroteaux-Lamy syndrome"],"catalyst":""},{"name":"Aldurazyme","genericName":"LARONIDASE","slug":"laronidase","phase":"marketed","mechanism":"Aldurazyme breaks down abnormal sugar molecules in the body to treat Mucopolysaccharidosis I.","indications":["Mucopolysaccharidosis, MPS-I"],"catalyst":""},{"name":"Kuvan","genericName":"SAPROPTERIN","slug":"sapropterin","phase":"marketed","mechanism":"Kuvan works by activating the enzyme Phenylalanine Hydroxylase to break down phenylalanine.","indications":["Reduce blood phenylalanine levels in PKU"],"catalyst":""},{"name":"Vosoritide Injection","genericName":"Vosoritide Injection","slug":"vosoritide-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMN 111","genericName":"BMN 111","slug":"bmn-111","phase":"phase_3","mechanism":"BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height.","indications":["Achondroplasia (to increase adult height)","Other skeletal dysplasias (under investigation)"],"catalyst":""},{"name":"BMN 165","genericName":"BMN 165","slug":"bmn-165","phase":"phase_3","mechanism":"BMN 165 is a gene therapy that delivers a functional copy of the GALNS gene to restore enzyme activity deficient in mucopolysaccharidosis IVA (Morquio A syndrome).","indications":["Mucopolysaccharidosis IVA (Morquio A syndrome)"],"catalyst":""},{"name":"BMN 333","genericName":"BMN 333","slug":"bmn-333","phase":"phase_2","mechanism":"BMN 333 is a small molecule that targets the enzyme alpha-N-acetylgalactosaminidase (NAGLU), which is deficient in patients with mucopolysaccharidosis type IIIB (MPS IIIB).","indications":["Mucopolysaccharidosis type IIIB (MPS IIIB)"],"catalyst":""},{"name":"Placebo/rhASB","genericName":"Placebo/rhASB","slug":"placebo-rhasb","phase":"phase_3","mechanism":"rhASB (recombinant human arylsulfatase B) is an enzyme replacement therapy that replaces deficient arylsulfatase B to break down glycosaminoglycans accumulated in Maroteaux-Lamy syndrome.","indications":["Maroteaux-Lamy syndrome (mucopolysaccharidosis VI)"],"catalyst":""},{"name":"BMN 110","genericName":"BMN 110","slug":"bmn-110","phase":"phase_3","mechanism":"BMN 110 is a gene therapy that delivers a functional copy of the HEXA gene to restore hexosaminidase A enzyme activity in patients with Tay-Sachs disease.","indications":["Tay-Sachs disease (late-infantile or juvenile onset)"],"catalyst":""},{"name":"BMN 110 - Every Other Week","genericName":"BMN 110 - Every Other Week","slug":"bmn-110-every-other-week","phase":"phase_3","mechanism":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.","indications":["Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)"],"catalyst":""},{"name":"BMN 110 - Weekly","genericName":"BMN 110 - Weekly","slug":"bmn-110-weekly","phase":"phase_3","mechanism":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.","indications":["Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)"],"catalyst":""},{"name":"N-acetylgalactosamine 4-sulfatase","genericName":"N-acetylgalactosamine 4-sulfatase","slug":"n-acetylgalactosamine-4-sulfatase","phase":"phase_3","mechanism":"N-acetylgalactosamine 4-sulfatase is an enzyme replacement therapy that replaces the deficient GALNS enzyme to break down keratan sulfate and chondroitin 6-sulfate in lysosomal storage disease.","indications":["Morquio A syndrome (mucopolysaccharidosis IVA)"],"catalyst":""},{"name":"Phenoptin","genericName":"Phenoptin","slug":"phenoptin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RDD to Palynziq","genericName":"RDD to Palynziq","slug":"rdd-to-palynziq","phase":"marketed","mechanism":"Palynziq is a recombinant phenylalanine ammonia-lyase (PAL) enzyme that breaks down phenylalanine, reducing blood phenylalanine levels in patients with phenylketonuria.","indications":["Phenylketonuria (PKU) in patients with blood phenylalanine levels ≥600 μmol/L"],"catalyst":""},{"name":"Rhttp1","genericName":"CERLIPONASE ALFA","slug":"cerliponase-alfa","phase":"marketed","mechanism":"Cerliponase alfa works by inhibiting the breakdown of a protein called tripeptidyl peptidase, which is deficient in patients with late-infantile neuronal ceroid lipofuscinosis.","indications":["Late-infantile neuronal ceroid lipofuscinosis"],"catalyst":""},{"name":"Roctavian","genericName":"VALOCTOCOGENE ROXAPARVOVEC","slug":"valoctocogene-roxaparvovec","phase":"marketed","mechanism":"Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein.","indications":["Severe hereditary factor VIII deficiency disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"BioMarin Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"BioMarin Pharmaceutical Inc. (BMRN) today reported its financial results for the fourth quarter and full year 2023. The company reported net product sales of $1.2 billion for the full year, a 10% increase compared to the prior year.","drugName":"","sentiment":"positive"},{"date":"2023-11-21","type":"deal","headline":"BioMarin Announces Collaboration with the National Institutes of Health (NIH) to Develop New Therapies for Rare Genetic Disorders","summary":"BioMarin Pharmaceutical Inc. (BMRN) today announced a collaboration with the National Institutes of Health (NIH) to develop new therapies for rare genetic disorders. The collaboration will focus on developing treatments for conditions such as hemophilia A and mucopolysaccharidosis type I.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"regulatory","headline":"BioMarin Receives FDA Approval for Vosoritide for the Treatment of Achondroplasia","summary":"BioMarin Pharmaceutical Inc. (BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved vosoritide for the treatment of achondroplasia, a rare genetic disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN1lCSXpfaU1hZjl2YkhMR3JqLUx3M2lKc0w5M0NGMXNuNmtUdVlVc2NlUlJkTkJ4MENKWTk5dHB1eW56VDVRRG00bEN4MmxTUlljVkZMSG5yZ3hkQ1RkdHFPaEJrYk9HWF9NM01FS2drdGhxVUFIb3pZMkpRM2l0RkhrWmxoMUZtN1ZaSENrUnhqcFdfRU00bDZBaHRqLTd2WmpmLXhCdW9qS1RSMWFPNlFzNmpvN3RYTFQzdlFuaU8?oc=5","date":"2026-02-16","type":"earnings","source":"TradingView","summary":"What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView","headline":"What to Expect From These Drug/Biotech Players This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQQjBYODg1Q1h3cTR6UGppY3BkTkVwNGQ0d052MHVOOGoycEt6WndEd2NUOXg4X0pjN1F1TEVoMTdSa0lqUzYxcEsxUkJjeUYtUFE2WjRtZWZXZkhwNDNNSmVJZzE1WDluVWVrUERfVzF6QkZ6VXRHMFhfTkdsdEZySThKdV9PbjJKakdHLUFTY203VVA3d2tCb21oQWh6RjY2djd5dllrX1poZ0pRNjI5V0VWSFNjUnhRR3d4NU9ReC13OVl6dHVQT0luclVrN2c4?oc=5","date":"2026-02-12","type":"regulatory","source":"Sahm","summary":"BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Sahm","headline":"BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1LVzQxbTd5SlM0VzVDWWU4dGxVUUk1SGFkc3RncGc4OFB5dTJfN1VQS3pzVGVWV3RtZjJ5NHBRc3FqLVBBTmMzS2pKRkxiQXhEeEhPWGs2ejVmTlRQUkZiRDhaTmg1TVNpRmc?oc=5","date":"2026-02-05","type":"deal","source":"Morningstar","summary":"The Best Biotech Stocks to Buy - Morningstar","headline":"The Best Biotech Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWFNLLWR2aktJMFEtWmZfMUNYSjA5MDM3dGNPQTRYMFRrYVg0V0ZLNWlXcHZOZXIyZW1Tbzh3czZqRWxvc1lSZjFTTXRHM0xhc21kMU5La3NZZEVmeTZBRW16YnlaSnJaMHV4TW1leUhiMHZHVWJvMHdFZDRyWENxc3NsWEcxclpSSkVj?oc=5","date":"2026-02-01","type":"pipeline","source":"Seeking Alpha","summary":"The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha","headline":"The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-30","type":"deal","source":"Insider Monkey","summary":"Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Insider Monkey","headline":"Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVEdPSDRaVnFhT3kyUUdoVWM4SmEyOF9KSE5PWXByTDFKbjB1eld5aU1JZXpUZU9MQldSZU1EMDBkMGlXQk13cnk0QU8tUmg1dWZnMzBnMjV4em9tdk1VUWQzcVhWWTU4WldNQnVMM0h2ODhZMlNoUlpfeVZva1BTSDJISGJTZWtZOFU0bkpJLUNycUV0UVE2MHFOeDd4VlEzb2xkSWE2dlJncjQ?oc=5","date":"2025-12-26","type":"pipeline","source":"Seeking Alpha","summary":"BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha","headline":"BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZTdHcTFtSEU2UmNucFZGdHlTNFN4aWlOeEVMdU9ycmVwR05DV0YtbjBXR0tlSnV6bnhoZ3JLWnlET1JJX25RMTBtejE4UVpZUDRfd2EwNE9UUEZmcy16SFlQSmxNRW9YX2pmLVI5TkRITXZwdWpTZlNMSnY2YXhYcTkzeVIwQ21IN0tkWDU0WmVTbzFyNW9Jd2FNU0NsRXl3VVg3U00zdUNGMWJLM1QxMUIwM3A?oc=5","date":"2025-12-19","type":"pipeline","source":"MedCity News","summary":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News","headline":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQVDJNXzYxZGJuUGxiLW5fQTMycHNxbHdrVjRleDZfWXp6NjZmSUd5WEtiXzZXeXVrUzUtWFJVUzVIU0hlQ2tKNGg0VU5ub3ZPN2lGNW9wblEyQXowVnl4UU10S2VHMUgwblU5dFZaWlQ5RWVjSzRUMEd0X0hQanNON1RDNmlsSHF3ckRIazFUQ3hQODhndDg5clBkcUprdmNheUJGZWlQX1o1SEo1MU45RQ?oc=5","date":"2025-08-12","type":"earnings","source":"The Business Journals","summary":"Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals","headline":"Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaFdYb2JKdUpKWW9BWTJxUDlDSmh1TGNpY0MxMmR6UVMxaTFEeEhjbWxXWG9vNEdZTHdWTTVyNjZHS1hDb1hBNmZSR1RQakZTUGRPY1BZU0xhR3hmN1lwcTAtMUhWbE51X1VKTWxzdFRTY1RLbXhHWnJyLUlLWEg3NDhCVVdMQ21wWHpQZXk0WDZMcGlUQ0RvTXBvLXVzcmhrMFFkY1pWSUFNUjUzQXBhVmNlTnR6VVVPcE44WEhCaXE?oc=5","date":"2025-08-01","type":"pipeline","source":"PR Newswire","summary":"BioMarin Announces Appointment of Ian T. Clark to Board of Directors - PR Newswire","headline":"BioMarin Announces Appointment of Ian T. Clark to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOV2FlU2I3aXgxTnF5VFhjMDJub1M1Nld1QTN2QkxNMlI3SGNpclh5ZlZGS2pTaTlJakotR21rN0tMclVEcVVoN3hETDRUdU8xdUVITk9MYW1nQjFjYksxOEpjNEtGRHY3cmpvWFdzV2lpRFByN01KT3pTNFNlUVFUUDFpN2JhOVIzOFNJbnIweTFUdlFLRUN6M3Y3R2k?oc=5","date":"2025-07-10","type":"pipeline","source":"Yahoo Finance","summary":"BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - Yahoo Finance","headline":"BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdTJ1eE1DaDg5cXI3WUFldktkbHJONGRNX2gyaXVUaWxVbzllYzhMN0pvUWlES0VpaHhOa3hoNFZqQlZGdVZFamNkaVZydkVfUnN4aVpFTHJIVVlNZW1jZFFRWFNVNjUyZFpKQzJRMldIVGNRYmZYNy1PTlRIQkVzNTNoQ0hsRW1vOVo5dWtvV3lqb3dkUmdHYnJPVURoMENPZDJRcFRQOXZzMUhaa1ZWM016V2RVR3JJaWZjaW5Pd2NUbXNibzBDaERXbDNXZ0s5?oc=5","date":"2025-07-01","type":"pipeline","source":"Investing.com","summary":"BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com","headline":"BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-30","type":"earnings","source":"simplywall.st","summary":"The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st","headline":"The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable","sentiment":"neutral"}],"patents":[{"drugName":"Vimizim","drugSlug":"elosulfase-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":400000000},{"drugName":"Aldurazyme","drugSlug":"laronidase","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":17,"phaseCounts":{"marketed":7,"phase_2":3,"phase_3":7},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Shire","Sanofi Genzyme","Pfizer"],"therapeuticFocus":["Rare genetic disorders","Hemophilia A","Mucopolysaccharidosis type I"],"financials":{"source":"sec_edgar","revenue":1313646000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":1313646000,"period":"2017-12-31"},{"value":1116854000,"period":"2016-12-31"},{"value":1116854000,"period":"2016-12-31"},{"value":889895000,"period":"2015-12-31"},{"value":889895000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":921930000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":348901000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7594022000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":57.28,"previousClose":56.22,"fiftyTwoWeekHigh":66.28,"fiftyTwoWeekLow":50.76,"fiftyTwoWeekRange":"50.76 - 66.28","fiftyDayAverage":58.35,"twoHundredDayAverage":56.54,"beta":0.29,"enterpriseValue":9894683648,"forwardPE":8.5,"priceToBook":1.81,"priceToSales":3.42,"enterpriseToRevenue":3.07,"enterpriseToEbitda":13.69,"pegRatio":0.65,"ebitda":722888000,"ebitdaMargin":22.4,"freeCashflow":402657984,"operatingCashflow":827993984,"totalDebt":642873024,"debtToEquity":10.6,"currentRatio":5.21,"returnOnAssets":5.6,"returnOnEquity":5.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":23,"targetMeanPrice":88.87,"targetHighPrice":120,"targetLowPrice":55,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.4,"institutionHeldPercent":101.2,"sharesOutstanding":192323359,"floatShares":191207884,"sharesShort":8501110,"shortRatio":3.94,"shortPercentOfFloat":4.4,"epsTrailing":1.8,"epsForward":6.73,"revenuePerShare":16.8,"bookValue":31.65,"officers":[{"age":57,"name":"Mr. Alexander  Hardy","title":"President, CEO & Director"},{"age":51,"name":"Mr. Brian R. Mueller CPA","title":"CFO & Executive VP"},{"age":54,"name":"Mr. George Eric Davis J.D.","title":"Executive VP, Chief Legal Officer & Secretary"},{"age":null,"name":"Ms. Cristin  Hubbard","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Dr. Gregory  Friberg M.D.","title":"Executive VP and Chief Research & Development Officer"},{"age":46,"name":"Ms. Rashmi Eshwar Ramchandani","title":"VP, Chief Accounting Officer & Principal Accounting Officer"},{"age":63,"name":"Dr. C. Greg Guyer Ph.D.","title":"Executive VP & CTO"},{"age":null,"name":"Dr. Kevin  Eggan Ph.D.","title":"Chief Scientific Officer & Senior VP of Research and Early Development"}],"industry":"Biotechnology","irWebsite":"http://investors.bmrn.com/index.cfm","website":"https://www.biomarin.com","phone":"415 506 6700"}}